Riluzole

Spécifications

1744-22-5Numéro CAS

605-724-6Numéro CE

6-(trifluoromethoxy)-1,3-benzothiazol-2-amineNom IUPAC

C8H5F3N2OSFormule chimique

234.2 g/molMasse molaire

riluzole; 1744-22-5; Rilutek; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; Riluzol; Riluzolum; 2-amino-6-trifluoromethoxybenzothiazole; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; RP 54274; Tiglutik; NSC-753433; NSC-759823; EXSERVAN; 7LJ087RS6F; BHV-0223; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; PK26124; RP54274; Teglutik; 2 Amino 6 trifluoromethoxybenzothiazole; TIGLUTIK KIT; PK 26124; RefChem:58435; N07XX02; 605-724-6; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-(trifluoromethoxy)-2-benzothiazolamine; PK-26124; C8H5F3N2OS; 2-Benzothiazolamine,6-(trifluoromethoxy)-; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; DTXSID3045192; Amino-2 trifluoromethoxy-6 benzothiazole; MLS000069369; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 2-Amino-6-(trifluoromethoxy)-benzothiazole; CHEMBL744; SMR000058231; MFCD00210213; NCGC00015882-09; 6-(trifluoromethoxy)benzothiazole-2-ylamine; Riluzol [INN-Spanish]; Riluzolum [INN-Latin]; 6-trifluoromethoxy-1,3-benzothiazol-2-ylamine; F3282-0020; DTXCID1025192; Rilutek (TN); CAS-1744-22-5; Amino-2 trifluoromethoxy-6 benzothiazole [French]; UNII-7LJ087RS6F; Riluzole, solid; Riluzole?; Riluzole [USAN:USP:INN:BAN]; BF-37; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; ALBB-006046; Riluzole (Rilutek); Prestwick-03A08; Riluzole (Standard); Tocris-0768; Opera_ID_548; RILUZOLE [USAN]; Lopac-R-116; RILUZOLE [INN]; RILUZOLE [JAN]; RILUZOLE [MI]; Prestwick0_000167; Prestwick1_000167; Prestwick2_000167; Prestwick3_000167; Spectrum2_000550; RILUZOLE [MART.]; Biomol-NT_000245; RILUZOLE [USP-RS]; RILUZOLE [WHO-DD]; cid_5070; Riluzole (JAN/USP/INN); RILUZOLE [EMA EPAR]; Lopac0_001064; SCHEMBL78905; BSPBio_000033; Riluzole - Bio-X trade mark; BIDD:GT0055; SPBio_000599; SPBio_001954; RILUZOLE [ORANGE BOOK]; BPBio1_000037; BPBio1_000837; CHEBI:8863; GTPL2326; orb1225931; orb1310698; RILUZOLE [USP IMPURITY]; RILUZOLE [USP MONOGRAPH]; SCHEMBL29359189; BDBM30705; HY-B0211R; Bio1_000416; Bio1_000905; Bio1_001394; GLXC-07553; HMS1773G08; HMS2089O19; HMS2094G07; HMS2233E14; HMS3263E10; HMS3371A09; HMS3657E13; HMS5079I20; HMS5171H17; Pharmakon1600-01505348; SMSSF-0055855; HY-B0211; QYB55203; Tiglutik (thickened oral suspension); Tox21_110252; Tox21_501064; AC-730; CCG-39528; EBC-11108; HB6093; MSK160656; NSC753433; NSC759823; s1614; SBB012436; STK503686; AKOS000265071; Tox21_110252_1; DB00740; FR27733; KS-5231; LP01064; NSC 753433; NSC 759823; SDCCGSBI-0051034.P003; 2-amino-6-trifluoromethoxy-benzothiazole; 6-(trifluoromethoxy)benzothiazol-2-amine; 6-trifluoromethoxy-2-amino-benzothiazole; NCGC00015882-01; NCGC00015882-02; NCGC00015882-03; NCGC00015882-04; NCGC00015882-05; NCGC00015882-06; NCGC00015882-07; NCGC00015882-08; NCGC00015882-10; NCGC00015882-11; NCGC00015882-12; NCGC00015882-13; NCGC00015882-15; NCGC00015882-18; NCGC00015882-26; NCGC00015882-28; NCGC00023141-02; NCGC00023141-04; NCGC00023141-05; NCGC00023141-06; NCGC00261749-01; 6-(trifluoromethoxy)-2-aminobenzothiazole; 6-trifluoromethoxybenzo[d]thiazol-2-amine; BR164340; ST038494; ST068834; SBI-0051034.P002; 2-Amino-6-(Trifluoromethoxy) Benzothiazole; DB-030335; A2423; EU-0101064; NS00005892; R1174; R3347; SW196805-4; EN300-23782; C07937; D00775; VU0239571-11; F004026; Q415744; SR-01000002997-3; BRD-K21283037-001-02-5; BRD-K21283037-001-20-7; BRD-K21283037-001-21-5; BRD-K21283037-003-03-9; BRD-K21283037-003-06-2; BRD-K21283037-003-11-2; Z164707762; Riluzole, 6-(Trifluoromethoxy)-1,3-benzothiazol-2-amine; Riluzole, United States Pharmacopeia (USP) Reference Standard; 6-Trifluoromethoxy-2-aminobenzothiazole; 6-(Trifluoromethoxy)-1,3-benzothiazol-2-amineSynonymes